I came across an interesting commentary by John Conley on the NIH’s refusal to exercise march-in rights under Bayh-Dole. The post is from January 2011 and has to do with the problems Genzyme has had producing an enzyme that helps patients with Fabry disease, which is caused by a genetic mutation that creates an enzyme deficiency. Genzyme has an exclusive license under NYU patents. Some Fabry patients appealed to the NIH to march-in and grant licenses to other manufacturers to produce the enzyme, but NIH has refused, making it appear that the agency as a matter of policy simply won’t ever march in.
By creating the march-in right, Congress expressed concern about the dark side of granting proprietary rights in publicly-funded technology. Does the NIH’s track record amount to a rejection of that concern?
Check out the insightful comment to Conley’s discussion by Robert Cook-Deegan, as well. Perhaps, as another commenter notes, the NIH is simply afraid of disrupting university exclusive licensing by marching in. Continue reading